BEIJING, May 24 (Xinhua) -- Hong Kong-listed WuXi Biologics (Cayman) Inc., a leading global biologics services provider that offers comprehensive, integrated and highly customizable services, announced Tuesday that it planned to invest 80 million Singapore dollars (about 380 million yuan) to build a modern biologics manufacturing base in Singapore.
This would be the company’s tenth biologics manufacturing base worldwide, the first Asian base outside China and the second overseas base following the one in Ireland.
With total capacity estimated at 4,500 liters, the base in Singapore would pioneer the application of the new generation of biologics manufacturing process (continuous production process) for commercial production. (Edited by Niu Huizhe, niuhuizhe@xinhua.org)
A single purchase
